DSSG Group: Breast

ER+/HER2- early breast cancer with intermediate-high or high risk of recurrence

The purpose of this study is to measure the safety and demonstrate the superiority of camizestrant +/- abemaciclib as compared to standard endocrine therapy +/- abemaciclib by assessment of invasive breast cancer-free survival

Premenopausal patients with ER-positive/HER2-negative early breast cancer

A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

ER+/HER2- early-stage breast cancer with ctDNA relapse.

To evaluate whether elacestrant can delay occurrence of distant metastasis or death when compared to standard endocrine therapy in ER+/HER2- patients with ctDNA relapse.

No new patients will be recruited to this study. The original study involved patients with breast cancer treated with Trastuzumab.If you participated in the CTRIAL-IE (ICORG) 08-01 CADY study on cardiac dysfunction in HER-2 positive breast cancer patients, please read this important data protection notice. Cancer Trials Ireland, in collaboration with Abbott Laboratories, is conducting a follow-up sub-study to re-test stored biological samples using advanced biomarker technology and review medical records for cardiovascular outcomes. This research aims to improve early detection of heart risks in breast cancer patients treated with Trastuzumab. Your data remains securely stored and protected, with strict access controls. If you wish to learn more, withdraw consent, or exercise your data rights, click here to read the full notice.

The study aims to:
(1) Evaluate the predictive capability of chosen cardiac biomarkers in forecasting cardiac dysfunction in breast cancer patients treated with Trastuzumab.
(2) Develop a predictive model using machine learning techniques based on the most accurate and sensitive combination of biomarkers.

Estrogen receptor positive (ER+), human epidermal receptor 2 negative (HER2-) early-stage, resected, invasive breast cancer without evidence of distant metastasis.

To measure how well imlunestrant works compared to standard hormone therapy in patients with early-stage breast cancer that is ER+ and HER2-.

Early or metastatic triple negative breast cancer (TNBC)

The main purpose of this study is to profile exosomes isolated from the plasma of women diagnosed with TNBC during routine treatment and follow up in the oncology clinic using Nanoparticle tracking analysis (NTA) and Raman/infra-red spectroscopy.

Female patients diagnosed with stage I-III breast cancer.

The main purpose of the study is to evaluate pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment.

Female patients with an investigator-assessed discrete breast abnormality of size > 1cm.

The main purpose of this study is to determine whether a microwave imaging system (Wavelia #2) can be used for the detection of breast cancer.

Patients with luminal A early breast cancer who had breast conserving surgery and endocrine therapy

The purpose of this study is to see whether a genomic test (looking at specific genes) of breast cancer tissue can be used to select women who can safely avoid radiation therapy because they have a low risk of the cancer coming back.

HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor.

The purpose of this study is to obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor.